GlobeImmune pulls plug on $75M IPO despite still-bubbling market

Damian Garde

After repeated delays, Colorado immunotherapy developer has finally called it quits on plans to raise up to $ 74.8 million in an IPO, citing poor conditions amid a prolonged boom in biotech debuts.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS